IRadimed Stock Price, News & Analysis (NASDAQ:IRMD) $41.73 -0.05 (-0.12%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$41.25▼$42.3950-Day Range$37.31▼$45.0652-Week Range$27.57▼$51.04Volume20,929 shsAverage Volume26,645 shsMarket Capitalization$526.22 millionP/E Ratio32.35Dividend YieldN/APrice Target$54.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability IRadimed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside29.4% Upside$54.00 Price TargetShort InterestHealthy1.05% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.59Based on 2 Articles This WeekInsider TradingSelling Shares$1.76 M Sold Last QuarterProj. Earnings Growth19.12%From $1.36 to $1.62 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.26 out of 5 starsMedical Sector11th out of 932 stocksSurgical & Medical Instruments Industry4th out of 93 stocks 3.5 Analyst's Opinion Consensus RatingIRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.00, IRadimed has a forecasted upside of 29.4% from its current price of $41.73.Amount of Analyst CoverageIRadimed has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.05% of the float of IRadimed has been sold short.Short Interest Ratio / Days to CoverIRadimed has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IRadimed has recently decreased by 19.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIRadimed does not currently pay a dividend.Dividend GrowthIRadimed does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIRadimed has received a 67.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Real-time vital parameter monitors for MRI machines", "Intravenous therapy equipment for MRI machines", and "ECG monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for IRadimed is -0.85. Previous Next 3.1 News and Social Media Coverage News SentimentIRadimed has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IRadimed this week, compared to 1 article on an average week.Search Interest7 people have searched for IRMD on MarketBeat in the last 30 days. MarketBeat Follows3 people have added IRadimed to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,756,432.00 in company stock.Percentage Held by Insiders42.60% of the stock of IRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.61% of the stock of IRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for IRadimed are expected to grow by 19.12% in the coming year, from $1.36 to $1.62 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IRadimed is 32.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 115.28.Price to Earnings Ratio vs. SectorThe P/E ratio of IRadimed is 32.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.14.Price to Book Value per Share RatioIRadimed has a P/B Ratio of 7.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IRadimed Stock (NASDAQ:IRMD)IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Read More IRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRMD Stock News HeadlinesDecember 6, 2023 | finance.yahoo.comWhy We Like The Returns At IRadimed (NASDAQ:IRMD)December 6, 2023 | finance.yahoo.comInsider Sell Alert: Director James Hawkins Sells Shares of iRadimed Corp (IRMD)December 10, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 30, 2023 | finance.yahoo.comIRADIMED CORPORATION Named a 2024 Most Successful Small-Cap Company in America by ForbesNovember 18, 2023 | morningstar.comiRadimed Corp IRMDNovember 17, 2023 | finance.yahoo.com5 Small Hidden Gems for the Rest of 2023November 14, 2023 | finance.yahoo.comInsider Sell: Director Anthony Vuoto Sells 3,055 Shares of iRadimed Corp (IRMD)November 6, 2023 | seekingalpha.comIRadimed: Which Way NowDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 5, 2023 | finance.yahoo.comIRadimed Corporation (NASDAQ:IRMD) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | finanznachrichten.deiRadimed Corporation: IRADIMED CORPORATION Announces Third Quarter 2023 Financial ResultsNovember 3, 2023 | chron.comIRadimed: Q3 Earnings SnapshotNovember 3, 2023 | finance.yahoo.comIRADIMED CORPORATION Announces Third Quarter 2023 Financial ResultsNovember 3, 2023 | finance.yahoo.comiRadimed Corp (IRMD) Reports 23% YoY Revenue Growth for Q3 2023November 2, 2023 | benzinga.comiRadimed's Earnings: A PreviewNovember 2, 2023 | markets.businessinsider.comHere's what to expect from iRadimed's earnings reportOctober 26, 2023 | finance.yahoo.comIRADIMED CORPORATION to Hold 2023 Third Quarter Financial Results Conference Call on November 3rdOctober 23, 2023 | finance.yahoo.comIRadimed Corporation's (NASDAQ:IRMD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?October 5, 2023 | finance.yahoo.comIRadimed's (NASDAQ:IRMD) investors will be pleased with their splendid 113% return over the last three yearsSeptember 23, 2023 | money.usnews.comIradimed CorpSeptember 22, 2023 | msn.com4 Top Profitable Stocks to Invest in Using Net Income RatioSeptember 13, 2023 | finance.yahoo.comInsider Sell: Roger Susi Sells 10,000 Shares of iRadimed Corp (IRMD)September 6, 2023 | finance.yahoo.comIRADIMED CORPORATION to Participate at Upcoming Investor ConferencesSeptember 4, 2023 | finance.yahoo.comWith a 41% stake, IRadimed Corporation (NASDAQ:IRMD) insiders have a lot riding on the companyAugust 31, 2023 | msn.comIradimed (IRMD) Price Target Increased by 6.21% to 58.14August 25, 2023 | msn.comIRadimed Continues Ploughing Along With Superb Economic CharacteristicsAugust 24, 2023 | finance.yahoo.comZacks.com featured highlights Perdoceo Education, Boot Barn and iRadimedSee More Headlines Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRadimed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRMD CUSIPN/A CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees123Year FoundedN/APrice Target and Rating Average Stock Price Target$54.00 High Stock Price Target$60.00 Low Stock Price Target$48.00 Potential Upside/Downside+29.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$1.29 Trailing P/E Ratio32.35 Forward P/E Ratio30.68 P/E GrowthN/ANet Income$12.83 million Net Margins25.92% Pretax Margin32.97% Return on Equity23.19% Return on Assets19.79% Debt Debt-to-Equity RatioN/A Current Ratio9.13 Quick Ratio7.65 Sales & Book Value Annual Sales$53.30 million Price / Sales9.87 Cash Flow$1.07 per share Price / Cash Flow38.90 Book Value$5.86 per share Price / Book7.12Miscellaneous Outstanding Shares12,610,000Free Float7,238,000Market Cap$526.22 million OptionableNot Optionable Beta0.87 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Roger E. Susi (Age 70)Founder, Chairman, CEO & President Comp: $586.04kMr. John F. Glenn (Age 61)CFO & Corporate Secretary Comp: $411.79kMr. Randy WaddellVice President of Worldwide Sales & MarketingMr. Steve KachelmeyerVice President of Regulatory Affairs & Quality AssuranceMr. Lynn NeuhardtVice President of Research & DevelopmentMr. Chris WilliamsonExecutive Vice President of Continuous Improvement & Information TechnologyMr. Matt GarnerControllerMore ExecutivesKey CompetitorsPulse BiosciencesNASDAQ:PLSEAtrionNASDAQ:ATRICVRxNASDAQ:CVRXSurmodicsNASDAQ:SRDXTreace Medical ConceptsNASDAQ:TMCIView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 5,251 shares on 11/30/2023Ownership: 0.042%Deutsche Bank AGBought 563 shares on 11/24/2023Ownership: 0.032%Walleye Capital LLCBought 5,128 shares on 11/21/2023Ownership: 0.041%Tudor Investment Corp Et AlBought 634 shares on 11/16/2023Ownership: 0.130%Legal & General Group PlcBought 7,567 shares on 11/15/2023Ownership: 0.070%View All Insider TransactionsView All Institutional Transactions IRMD Stock Analysis - Frequently Asked Questions Should I buy or sell IRadimed stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares. View IRMD analyst ratings or view top-rated stocks. What is IRadimed's stock price target for 2024? 1 Wall Street analysts have issued 1-year price objectives for IRadimed's shares. Their IRMD share price targets range from $48.00 to $60.00. On average, they expect the company's share price to reach $54.00 in the next year. This suggests a possible upside of 29.4% from the stock's current price. View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts. How have IRMD shares performed in 2023? IRadimed's stock was trading at $28.29 at the start of the year. Since then, IRMD stock has increased by 47.5% and is now trading at $41.73. View the best growth stocks for 2023 here. Are investors shorting IRadimed? IRadimed saw a drop in short interest in November. As of November 15th, there was short interest totaling 80,000 shares, a drop of 19.8% from the October 31st total of 99,700 shares. Based on an average daily trading volume, of 33,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.1% of the company's stock are sold short. View IRadimed's Short Interest. When is IRadimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024. View our IRMD earnings forecast. How were IRadimed's earnings last quarter? IRadimed Co. (NASDAQ:IRMD) announced its quarterly earnings data on Friday, November, 3rd. The medical equipment provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.06. The medical equipment provider earned $16.51 million during the quarter, compared to analyst estimates of $16.21 million. IRadimed had a net margin of 25.92% and a trailing twelve-month return on equity of 23.19%. How often does IRadimed pay dividends? What is the dividend yield for IRadimed? IRadimed declared a dividend on Monday, February 6th. Stockholders of record on Monday, February 13th will be given a dividend of $1.05 per share on Tuesday, February 21st. This represents a yield of 2.54%. The ex-dividend date is Friday, February 10th. This is a boost from the stock's previous dividend of $1.00. Read our dividend analysis for IRMD. What ETF holds IRadimed's stock ? Ballast Small/Mid Cap ETF holds 19,404 shares of IRMD stock, representing 0.98% of its portfolio. What other stocks do shareholders of IRadimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR). Who are IRadimed's major shareholders? IRadimed's stock is owned by many different institutional and retail investors. Top institutional investors include RK Capital Management LLC (2.39%), Ranger Investment Management L.P. (1.68%), Northern Trust Corp (0.66%), Rice Hall James & Associates LLC (0.61%), Bank of New York Mellon Corp (0.44%) and Los Angeles Capital Management LLC (0.42%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi. View institutional ownership trends. How do I buy shares of IRadimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IRMD) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRadimed Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.